

PURE BIOSCIENCE

Form 4

April 07, 2008

FORM 4
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
KRALL MICHAEL L

(Last) (First) (Middle)

**C/O PURE BIOSCIENCE, 1725
GILLESPIE WAY**

(Street)

EL CAJON, CA 92020

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading
Symbol
PURE BIOSCIENCE [PURE]

3. Date of Earliest Transaction
(Month/Day/Year)
04/03/2008

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

☒ Director ☐ 10% Owner
☒ Officer (give title below) ☐ Other (specify
below)

Chief Executive Officer

6. Individual or Joint/Group Filing(Check
Applicable Line)
☒ Form filed by One Reporting Person
☐ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount (1) (A) or (D) Price		
Common Stock	04/03/2008		A		36,543 (1) A \$ 0.53	693,388 (2)	D
Common Stock	04/03/2008		S		36,543 (1) D \$ 6	693,388 (2)	D
Common Stock	04/04/2008		A		19,000 (1) A \$ 0.53	693,388 (2)	D
Common Stock	04/04/2008		S		19,000 (1) D \$ 5.89	693,388 (2)	D
Common Stock	04/07/2008		A		11,957 (1) A \$ 0.53	693,388 (2)	D

Edgar Filing: PURE BIOSCIENCE - Form 4

Common Stock 04/07/2008 S 11,957 ⁽¹⁾ D \$ 5.53 693,388 ⁽²⁾ D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	\$ 0.53	04/03/2008		M		36,543		05/22/1998	12/19/2008	Common Stock	36,543
Stock Options	\$ 0.53	04/04/2008		M		19,000		05/22/1998	12/19/2008	Common Stock	19,000
Stock Options	\$ 0.53	04/07/2008		M		11,957		05/22/1998	12/19/2008	Common Stock	11,957

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director 10% Owner Officer Other
KRALL MICHAEL L C/O PURE BIOSCIENCE 1725 GILLESPIE WAY EL CAJON, CA 92020	X Chief Executive Officer

Signatures

/s/ Dennis Brovarone Attorney-in-fact for Michael L. Krall

04/07/2008

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) 10b5-1 Sale Plan Transactions

(2) Incorporates all transactions being reported on this Form 4.

Remarks:

There are no other changes to previously reported derivative securities.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.